BioMarin agreed to shell out approximately $270 million for Inozyme Pharma, a developer whose treatments target the PPi-adenosine pathway, a key regulator of bone health and blood vessel function.

I could populate this whole Stockwatch with them if I wanted to. But I don't want to, and here's why: I have a separate column for that, the Bullpen Report, which will come out Tuesday.

Certain developments from the weekend are probably too obvious to mention here. John Means and Alek Manoah both having UCL damage, for instance. What more needs to be said? Means has already been ...

Looming tariffs and recent job cuts from Washington have impacted two of the largest biotech tools companies that released first-quarter results this past week, prompting one to lower its earnings ...